Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155580 · ClinicalTrials.gov registry record · Phase 1
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT04155580: Clinical Trial Phase 1 study, sponsored by Astex Pharmaceuticals.
NCT04155580 is a Phase 1 study that was terminated before completion, run by Astex Pharmaceuticals. The registered enrollment target is 68 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04155580, a Phase 1 study, was terminated before completion, sponsored by Astex Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.
Interventions
- DRUG ASTX727
- DRUG ASTX660
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2020-06-12 |
| Est. Completion | 2022-01-14 |
| Phase | Phase 1 |
Why NCT04155580 stopped before completion
NCT04155580 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 2 interventions - of which ASTX727 is the first listed.
NCT04155580 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04155580 about?
NCT04155580 is a clinical study titled "A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)". To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.
What is the current status of trial NCT04155580?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2020-06-12. Estimated completion is 2022-01-14.
What interventions are being tested in trial NCT04155580?
The interventions under investigation include: ASTX727 (DRUG), ASTX660 (DRUG).
Who is sponsoring clinical trial NCT04155580?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04155580's enrollment target sits among peer trials
68 776th of 2000 higher than 1,219 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI